Subsequently, second- and third-generation ABL inhibitors, such as nilotinib, olverembatinib, and asciminib, have been developed to provide a more powerful inhibition of BCR–ABL and alleviate imatinib resistance in patients with CML with these mutations (18–22). This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.